The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
Investor's Business Daily on MSN
Two medical stocks skyrocket after demolishing views — and one is about to break out
Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter ...
Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances ...
TAMPA, Fla. (WFLA) — A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration. The FDA announced Thursday that the device, Optune Pax, ...
Novocure markets a battery-powered device for brain cancer patients that uses electric fields that inhibit tumor growth. A phase 3 trial recently showed a significant survival benefit for pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results